| Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2020: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2019: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
In this research, we tried to apply the unique technology for the development of fluorescent probes, which has been established by our group, to not only life sciences but also drug discovery and clinical medicine. In particular, 1) We successfully developed a fluorescent probe for hypoxia, azoSiR640, 2) We have successfully developed a basic scaffold for an activatable fluorescent probe, which can be internalized into the cells through the glucose transporter (GLUT), 3) We have successfully developed a selective inhibitor for hydrogen sulfide (H2S) and reactive sulfur species-producing enzyme, 3-mercaptopyruvate sulfurtransferase (3MST).
|
